平田 賢郎

Medicine & Life Sciences

1. Helicobacter pylori 100%
2. Stomach Neoplasms 46%
3. Rifabutin 32%
4. Drug Therapy 30%
5. Metronidazole 30%
6. Esophageal Squamous Cell Carcinoma 26%
7. Stomach 25%
8. sitafloxacin 25%
9. MicroRNAs 24%
10. Neoplasms 23%
11. Pyogenic Granuloma 21%
12. Survival 20%
13. Microsatellite Instability 18%
14. Barrett Esophagus 17%
15. Pancreatic Neoplasms 16%
16. Confidence Intervals 16%
17. Alcoholics 16%
18. Metaplasia 16%
19. Clarithromycin 16%
20. Therapeutics 15%
21. Capsule Endoscopy 15%
22. Amoxicillin 15%
23. Qingdai compound 15%
24. Japan 14%
25. Mutation 14%
26. Dyspepsia 14%
27. Gastroesophageal Reflux 13%
28. Safety 13%
29. Neoplastic Stem Cells 12%
30. Gallstones 12%
31. Nivolumab 12%
32. ramucirumab 11%
33. Odds Ratio 11%
34. Double-Balloon Enteroscopy 11%
35. 130-nm albumin-bound paclitaxel 11%
36. Pancreatic Intraductal Neoplasms 11%
37. Meta-Analysis 10%
38. Down-Regulation 10%
39. Esophagogastric Junction 10%
40. Hand-Foot Syndrome 10%
41. Colorectal Neoplasms 10%
42. Melanoma 10%
43. Ipilimumab 10%
44. Microsatellite Repeats 9%
45. Melanosis 9%
46. Prospective Studies 9%
47. Immediate Hypersensitivity 9%
48. Esophageal Diseases 9%
49. Ulcerative Colitis 9%
50. Hemorrhage 9%